Aug. 3 IPO action brief: Braveheart Bio's $300M deal leads the week, but retail access is unverified (2026)

August 3, 2026 is a regular NYSE trading day. The core session is scheduled for 9:30 a.m. to 4:00 p.m. ET, and the date is not on the 2026 holiday or early-close list. 1

Today's spotlight: Braveheart Bio (BRVE)

Status: Expected to price before its Nasdaq debut on August 6. Public calendar data shows 18.8 million shares at $15–$17, for an estimated $300 million deal. A separate IPO pricing date is not disclosed. 2

Minimum buy-in: Not available through a verified public retail allocation. Broker access: No public order window was verified through Robinhood, Fidelity, Schwab, E*TRADE, or Webull. If BRVE appears in an app after listing, that would be ordinary stock trading, not proof of IPO access.

Braveheart Bio is a clinical-stage biotech developing BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy, a disease in which the heart muscle becomes abnormally thick. The company says it plans global Phase 3 trials in obstructive and non-obstructive HCM. 3

Why it matters: this is the largest clearly sized deal on the current US calendar, but it remains a clinical-stage bet. The real test is whether global Phase 3 work confirms the earlier data.

One number: In a 42-patient Phase 2 obstructive-HCM study, the filing reports an 86% complete-response rate at Week 12 in one cohort. More than 300 people had been dosed globally by June 9, 2026. Hengrui, the Chinese partner, designed and ran the studies; they were not the planned global Phase 3 program. 3

The risk to monitor: Braveheart has no product revenue and depends on one lead candidate. Its filing reports a $14.28 million net loss in Q1 2026 and an $80.33 million accumulated deficit as of March 31, 2026. The next hard milestone is the planned Phase 3 start in the second half of 2026; delays or failed replication could change the story quickly. 3

Actionable now

No US IPO allocation met the public evidence bar for an open or 48-hour deadline window. The calendars show offerings but no mainstream-broker path; the NYSE filing page showed no filed deals on its August 3 update. 4 5 6

Ticker	Price range	Minimum buy-in	Deadline	Verified brokers	Status
None verified	—	—	No public US allocation window found	None publicly verified	Watch only

BRVE, ATTO, and VOGX are listing-watch names until a public allocation notice says otherwise.

Market pulse

Biotech is carrying the near-term calendar. Renaissance lists four current US candidates, including Braveheart, Attovia, Vogenx, and River City Bank. IPOScoop estimates the three biotech deals at $300 million, $200 million, and $75 million. 4 5
Terms are arriving late. IPOScoop dates Braveheart’s range disclosure to July 30 and Attovia’s and Vogenx’s to July 29. Final price and allocation remain open questions. 2 7 8
No public oversubscription multiple or retail-allocation confirmation was disclosed in the accepted sources. A $300 million deal can be important without telling you whether an ordinary brokerage customer can buy at the IPO price.

HK desk

NASN TECH (2261) is open and closing soon. The offer range is HK$10.42–HK$11.18 for a 100-share board lot. That makes the face-value minimum HK$1,042 at the low end, before fees. The noon Hong Kong deadline on August 4 converts to 04:00 on August 4 in this brief’s display time. Listing is August 7. 9 10

NASN TECH develops brake-by-wire systems for intelligent-driving vehicles. ET Net says its customers are mainly Chinese automakers and that it ranked among China’s top three domestic providers by 2025 sales volume. Phillip Securities corroborates the terms and dates. This is a Hong Kong public offer, not a US broker allocation. 10 11

On the radar: August 3–17

The calendar gives no separate pricing date, so none is inferred.

Deal	Pricing date	Expected listing	Terms	Why watch
Attovia Therapeutics (ATTO)	Not separately disclosed	Aug. 5	12.5M shares at $15–$17; est. $200M	Phase 1 immune-disease biotech with no products on the market or product-sales revenue. 7
Braveheart Bio (BRVE)	Not separately disclosed	Aug. 6	18.8M shares at $15–$17; est. $300M	Largest deal in the current calendar; Phase 3 HCM execution is the test. 2
Vogenx (VOGX)	Not separately disclosed	Aug. 6	6.25M shares at $11–$13; est. $75M	Phase 2 metabolic biotech; its lead candidate has never produced revenue. 8